Next Article in Journal
Megaprosthesis for Metastatic Bone Disease—A Comparative Analysis
Previous Article in Journal
Comprehensive Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of a Real-World Healthcare Claims Database
Article

STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma

1
National Medical Research Center for Hematology, Ministry of Health of Russian Federation, 125167 Moscow, Russia
2
School of Medicine, Lomonosov Moscow State University, 119991 Moscow, Russia
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3449-3459; https://doi.org/10.3390/curroncol29050278
Received: 31 March 2022 / Revised: 7 May 2022 / Accepted: 8 May 2022 / Published: 10 May 2022
Primary mediastinal B-cell lymphoma (PMBCL) is the only non-Hodgkin’s lymphoma variant responding to immune checkpoint inhibitor (ICI) therapy, approximately in half of the cases; however, no molecular markers predicting a response to ICI therapy in PMBCL have been described so far. In this study, we assessed the incidence of the loss of heterozygosity (LOH), elevated microsatellite alteration at selected tetranucleotides (EMAST), and microsatellite instability (MSI) in the tumor genomes of 72 patients with PMBCL undergoing high-dose chemotherapy treatment at the National Research Center for Hematology (Moscow, Russia). Tumor DNA was isolated from biopsy samples taken at diagnosis. Control DNA was isolated from the blood of patients in complete remission or from buccal epithelium. STR-profiles for LOH and EMAST were assessed by PCR with COrDIS Plus multiplex kit (Gordiz Ltd., Moscow, Russia). LOH was detected in 37 of 72 patients (51.4%). EMAST was found in 40 patients (55.5%); 24 had a combination of EMAST with LOH. MSI-high was not found, while MSI-low was detected only in one patient. The association of certain genetic lesions with the clinical outcome in patients receiving treatment according to the standard clinical protocol R-Da-EPOCH-21 has been estimated (58 patients out of 72) and no associations with the worst overall or event-free survival were found. View Full-Text
Keywords: PMBCL; LOH; EMAST; MSI; microsatellite stability (MSS) PMBCL; LOH; EMAST; MSI; microsatellite stability (MSS)
Show Figures

Figure 1

MDPI and ACS Style

Risinskaya, N.; Mangasarova, Y.; Nikulina, E.; Kozhevnikova, Y.; Chabaeva, J.; Yushkova, A.; Magomedova, A.; Kulikov, S.; Julhakyan, H.; Kravchenko, S.; Sudarikov, A. STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma. Curr. Oncol. 2022, 29, 3449-3459. https://doi.org/10.3390/curroncol29050278

AMA Style

Risinskaya N, Mangasarova Y, Nikulina E, Kozhevnikova Y, Chabaeva J, Yushkova A, Magomedova A, Kulikov S, Julhakyan H, Kravchenko S, Sudarikov A. STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma. Current Oncology. 2022; 29(5):3449-3459. https://doi.org/10.3390/curroncol29050278

Chicago/Turabian Style

Risinskaya, Natalya, Yana Mangasarova, Elena Nikulina, Yana Kozhevnikova, Julia Chabaeva, Anna Yushkova, Aminat Magomedova, Sergey Kulikov, Hunan Julhakyan, Sergey Kravchenko, and Andrey Sudarikov. 2022. "STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma" Current Oncology 29, no. 5: 3449-3459. https://doi.org/10.3390/curroncol29050278

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop